Proteomics analysis identified peroxiredoxin 2 involved in early-phase left ventricular impairment in hamsters with cardiomyopathy.
Kentaro KuzuyaSahoko IchiharaYuka SuzukiChisa InoueGaku IchiharaSyota KurimotoShinji OikawaPublished in: PloS one (2018)
Given the hypothesis that inflammation plays a critical role in the progression of cardiovascular diseases, the aim of the present study was to identify new diagnostic and prognostic biomarkers of myocardial proteins involved in early-phase cardiac impairment, using proteomics analysis. Using the two-dimensional fluorescence difference gel electrophoresis (2D-DIGE) combined with MALDI-TOF/TOF tandem mass spectrometry, we compared differences in the expression of proteins in the whole left ventricles between control hamsters, dilated cardiomyopathic hamsters (TO-2), and hypertrophy cardiomyopathic hamsters (Bio14.6) at 6 weeks of age (n = 6, each group). Proteomic analysis identified 10 protein spots with significant alterations, with 7 up-regulated and 3 down-regulated proteins in the left ventricles of both TO-2 and Bio 14.6 hamsters, compared with control hamsters. Of the total alterations, peroxiredoxin 2 (PRDX2) showed significant upregulation in the left ventricles of TO-2 and Bio 14.6 hamsters. Our data suggest that PRDX2, a redox regulating molecule, is involved in early-phase left ventricular impairment in hamsters with cardiomyopathy.
Keyphrases
- left ventricular
- mass spectrometry
- heart failure
- tandem mass spectrometry
- liquid chromatography
- high performance liquid chromatography
- cardiovascular disease
- hypertrophic cardiomyopathy
- oxidative stress
- acute myocardial infarction
- transcription factor
- high resolution
- mitral valve
- cell proliferation
- cardiac resynchronization therapy
- metabolic syndrome
- signaling pathway
- binding protein
- left atrial
- aortic stenosis
- long non coding rna
- single molecule
- aortic valve
- solid phase extraction
- transcatheter aortic valve replacement
- high resolution mass spectrometry